Literature DB >> 11257709

Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1.

B J Boyle1, X Y Zhao, P Cohen, D Feldman.   

Abstract

PURPOSE: We determined that insulin-like growth factor binding protein 3 (IGFBP-3) induction by 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) is a necessary component of 1,25-(OH)(2)D(3) mediated growth inhibition of the LNCaP human prostate cancer cell line. In addition, induction of the cyclin dependent kinase inhibitory protein p21/WAF/CIP1 by 1,25-(OH)(2)D(3) is mediated by IGFBP-3.
MATERIALS AND METHODS: Induction of IGFBP-3 by 1,25-(OH)(2)D(3) was determined by enzyme-linked immunosorbent assay for IGFBP-3 protein and by Northern blot analysis for IGFBP-3 messenger (m) RNA. Growth assays for LNCaP cells were determined by measuring DNA content. The contribution of IGFBP-3 toward 1,25-(OH)(2)D(3) mediated growth inhibition was determined by adding either antisense oligonucleotides or immuno-neutralizing antibodies to culture media of growth assays. Regulation of p21/WAF/CIP1 was determined by Western blot analysis.
RESULTS: Adding 1,25-(OH)(2)D(3) to LNCaP prostate cancer cells demonstrated that 1,25-(OH)(2)D(3) significantly up-regulated IGFBP-3 at the mRNA and protein levels in these cells approximately 3-fold over control levels. Also, adding IGFBP-3 protein to LNCaP cell growth medium inhibited LNCaP cell growth. Interestingly adding IGFBP-3 antisense oligonucleotides or antibodies directed toward IGFBP-3 abolished the growth inhibitory actions of 1,25-(OH)(2)D(3), indicating that this effect is IGFBP-3 dependent. Furthermore, to connect the mechanisms of IGFBP-3 and 1,25-(OH)(2)D(3) mediated growth inhibition we demonstrated that IGFBP-3 up-regulates the expression of p21/WAF1 protein to approximately 2-fold over the control level. Adding an IGFBP-3 immuno-neutralizing antibody completely prevented the 1,25-(OH)(2)D(3) induced up-regulation of p21/WAF1.
CONCLUSIONS: 1,25-(OH)(2)D(3) up-regulates IGFBP-3 in the LNCaP cell line at the mRNA and protein levels. The growth inhibitory action of 1,25-(OH)(2)D(3) on LNCaP cells depends on active IGFBP-3, as evidenced by the loss of growth inhibition induced by IGFBP-3 antisense oligonucleotide and immuno-neutralization experiments. A possible connection between IGFBP-3 and 1,25-(OH)(2)D(3) lies in the cyclin dependent kinase inhibitory protein p21/WAF1 since IGFBP-3 and 1,25-(OH)(2)D(3) each up-regulate this protein and both inhibit LNCaP cell growth. Therefore, we hypothesize that the mechanism of action by which IGFBP-3 and 1,25-(OH)(2)D(3) induce growth inhibition is the induction of p21/WAF1 because IGFPB-3 immuno-neutralizing antibodies completely abrogate the 1,25-(OH)(2)D(3) mediated up-regulation of p21/WAF1 and growth inhibition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257709

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  43 in total

Review 1.  Vitamin D and cancer: a review of molecular mechanisms.

Authors:  James C Fleet; Marsha DeSmet; Robert Johnson; Yan Li
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

2.  Dietary vitamin D and vitamin D receptor level modulate epithelial cell proliferation and apoptosis in the prostate.

Authors:  Pavlo L Kovalenko; Zhentao Zhang; Jun-Ge Yu; Yan Li; Steven K Clinton; James C Fleet
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-11

3.  Vitamin d for the management of prostate cancer.

Authors:  Masood A Khan; Alan W Partin
Journal:  Rev Urol       Date:  2004

4.  Is there any correlation between vitamin D insufficiency and diabetic retinopathy?

Authors:  Shokoufeh Bonakdaran; Nasser Shoeibi
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

Review 5.  Vitamin D and differentiation in cancer.

Authors:  Elzbieta Gocek; George P Studzinski
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

6.  EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I.

Authors:  Munenori Takaoka; Caitlin E Smith; Michael K Mashiba; Takaomi Okawa; Claudia D Andl; Wafik S El-Deiry; Hiroshi Nakagawa
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-10-06       Impact factor: 4.052

7.  Reassessing the Association between Circulating Vitamin D and IGFBP-3: Observational and Mendelian Randomization Estimates from Independent Sources.

Authors:  Vanessa Y Tan; Kalina M Biernacka; Tom Dudding; Carolina Bonilla; Rebecca Gilbert; Robert C Kaplan; Qi Qibin; Alexander Teumer; Richard M Martin; Claire M Perks; Nicholas J Timpson; Jeff M P Holly
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-08-02       Impact factor: 4.254

8.  Vitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity.

Authors:  Songcang Chen; Christopher S Law; David G Gardner
Journal:  J Steroid Biochem Mol Biol       Date:  2009-12-02       Impact factor: 4.292

9.  1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1.

Authors:  Pavlo L Kovalenko; Zhentao Zhang; Min Cui; Steve K Clinton; James C Fleet
Journal:  BMC Genomics       Date:  2010-01-13       Impact factor: 3.969

10.  Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.

Authors:  Jheri J Dupart; Jonathan C Trent; Ho-Young Lee; Kenneth R Hess; Andrew K Godwin; Takahiro Taguchi; Wei Zhang
Journal:  Mol Cancer       Date:  2009-11-10       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.